Moneycontrol PRO

Hold Alembic Pharma; target of Rs 720: ICICI Direct

ICICI Direct recommended hold rating on Alembic Pharma with a target price of Rs 720 in its research report dated May 04, 2022.

May 05, 2022 / 02:01 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Alembic Pharma

Alembic Pharma operates in international generics (US:31% & exUS: 15% in FY22), domestic branded (36% in FY22) and API (18% in FY22). • Domestic business has 1.5% of market share of IPM with three brands in the top 100. Going ahead, emphasis is on specialty segment with 94% of new launches being specialty products • The company has invested ~ Rs 1800 crore in recent years in facilities geared mainly towards US formulations. As of FY22, it has filed 230 ANDA and has 160 approvals with 105 launches in the US.


We maintain HOLD rating on the stock as current levels have priced in the challenges due to slower offtake in US base business as well as impending USFDA clearances. Valued at Rs 720 i.e. 20x P/E on FY24E EPS of Rs 35.9

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 5, 2022 02:01 pm
ISO 27001 - BSI Assurance Mark